Published in PLoS One on July 02, 2008
The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res (2009) 3.40
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet (2009) 2.40
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci (2009) 1.86
Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res (2010) 1.79
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A (2011) 1.60
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol (2016) 1.41
Complement in age-related macular degeneration: a focus on function. Eye (Lond) (2011) 1.39
Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci U S A (2009) 1.36
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retin Eye Res (2013) 1.29
Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. J Pathol (2013) 1.24
Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24
Progress and Trends in Complement Therapeutics. Adv Exp Med Biol (2013) 1.20
Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res (2014) 1.17
Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol (2011) 1.16
The role of the immune response in age-related macular degeneration. Int J Inflam (2013) 1.16
Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Mol Aspects Med (2012) 1.16
Complement factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 1.14
Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm (2012) 1.14
The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol (2010) 1.12
Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics (2009) 1.08
Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts. Free Radic Biol Med (2009) 1.06
Complement dysregulation in AMD: RPE-Bruch's membrane-choroid. Mol Aspects Med (2012) 1.03
The complotype: dictating risk for inflammation and infection. Trends Immunol (2012) 1.03
A2E accumulation influences retinal microglial activation and complement regulation. Neurobiol Aging (2012) 1.01
Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PLoS One (2012) 1.01
Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem (2012) 1.01
Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration. Exp Eye Res (2009) 0.99
Novel role for the innate immune receptor Toll-like receptor 4 (TLR4) in the regulation of the Wnt signaling pathway and photoreceptor apoptosis. PLoS One (2012) 0.98
Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration. Hum Mol Genet (2013) 0.97
Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther (2012) 0.96
A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One (2014) 0.96
Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol (2010) 0.95
Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol (2015) 0.94
Gene expression changes in aging retinal microglia: relationship to microglial support functions and regulation of activation. Neurobiol Aging (2013) 0.93
C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology (2010) 0.92
Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels. PLoS One (2014) 0.92
The complement component 5 gene and age-related macular degeneration. Ophthalmology (2009) 0.92
Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks. Mediators Inflamm (2013) 0.91
Interleukin-17 retinotoxicity is prevented by gene transfer of a soluble interleukin-17 receptor acting as a cytokine blocker: implications for age-related macular degeneration. PLoS One (2014) 0.91
Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol (2013) 0.91
Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration. Prog Retin Eye Res (2015) 0.90
Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report. J Transl Med (2013) 0.89
Zinc supplementation inhibits complement activation in age-related macular degeneration. PLoS One (2014) 0.86
Complement pathway biomarkers and age-related macular degeneration. Eye (Lond) (2015) 0.86
The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d. PLoS One (2013) 0.85
Complement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged mice. Invest Ophthalmol Vis Sci (2012) 0.85
Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One (2015) 0.85
The role of CRP and inflammation in the pathogenesis of age-related macular degeneration. Biochem Med (Zagreb) (2012) 0.85
A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population. PLoS One (2011) 0.84
Inflammatory biomarkers in osteoarthritis. Osteoarthritis Cartilage (2015) 0.84
[Therapy approaches for geographic atrophy]. Ophthalmologe (2010) 0.83
Estimating the predictive ability of genetic risk models in simulated data based on published results from genome-wide association studies. Front Genet (2014) 0.83
Light induces NLRP3 inflammasome activation in retinal pigment epithelial cells via lipofuscin-mediated photooxidative damage. J Mol Med (Berl) (2015) 0.83
Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration. Sci Rep (2015) 0.83
STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration. Curr Mol Med (2016) 0.83
Differential DNA methylation identified in the blood and retina of AMD patients. Epigenetics (2015) 0.83
Association analysis of genetic and environmental risk factors in the cuticular drusen subtype of age-related macular degeneration. Mol Vis (2012) 0.82
Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue. J Immunol Res (2014) 0.81
Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr⁴⁰²His polymorphism. Mol Vis (2012) 0.81
Genetic variation in complement regulators and susceptibility to age-related macular degeneration. Immunobiology (2011) 0.81
Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD. Immun Ageing (2016) 0.81
Fit for the Eye: Aptamers in Ocular Disorders. Nucleic Acid Ther (2016) 0.80
[Etiology and pathogenesis of age-related macular degeneration]. Ophthalmologe (2013) 0.80
A profile of transcriptomic changes in the rd10 mouse model of retinitis pigmentosa. Mol Vis (2014) 0.79
Subretinal infiltration of monocyte derived cells and complement misregulation in mice with AMD-like pathology. Adv Exp Med Biol (2014) 0.79
The role of macrophage class a scavenger receptors in a laser-induced murine choroidal neovascularization model. Invest Ophthalmol Vis Sci (2013) 0.79
Associations of complement factor B and complement component 2 genotypes with subtypes of polypoidal choroidal vasculopathy. BMC Ophthalmol (2014) 0.79
Pathological Effects of Mutant C1QTNF5 (S163R) Expression in Murine Retinal Pigment Epithelium. Invest Ophthalmol Vis Sci (2015) 0.78
Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? J Clin Med (2014) 0.78
Complement Component C5a Primes Retinal Pigment Epithelial Cells for Inflammasome Activation by Lipofuscin-mediated Photooxidative Damage. J Biol Chem (2015) 0.78
Complementing apolipoprotein secretion by cultured retinal pigment epithelium. Proc Natl Acad Sci U S A (2011) 0.78
Acute phase proteins are major clients for the chaperone action of α₂-macroglobulin in human plasma. Cell Stress Chaperones (2012) 0.78
Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol (2016) 0.78
Complement factor B polymorphism 32W protects against age-related macular degeneration. Mol Vis (2011) 0.78
CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and choroidal macrophages in the postmortem human eye. Mol Vis (2015) 0.78
Inflammaging in skin and other tissues - the roles of complement system and macrophage. Inflamm Allergy Drug Targets (2014) 0.77
Sequence and Expression of Complement Factor H Gene Cluster Variants and Their Roles in Age-Related Macular Degeneration Risk. Invest Ophthalmol Vis Sci (2016) 0.77
Lack of association of CFD polymorphisms with advanced age-related macular degeneration. Mol Vis (2010) 0.77
Nitrite Modification of Extracellular Matrix Alters CD46 Expression and VEGF Release in Human Retinal Pigment Epithelium. Invest Ophthalmol Vis Sci (2015) 0.76
Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? Autoimmun Rev (2017) 0.76
Inflammatory Mechanisms of Age-related Macular Degeneration. Int Ophthalmol Clin (2015) 0.76
Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration. PLoS One (2015) 0.76
Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature Human Adipocytes. J Ophthalmol (2015) 0.75
Complement factor B polymorphism (rs641153) and susceptibility to age-related macular degeneration: evidence from published studies. Int J Ophthalmol (2013) 0.75
Associations of 6p21.3 Region with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Sci Rep (2016) 0.75
Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can Suppress Neovascularization of Human Umbilical Vein Endothelial Cells: An in vitro Study. PLoS One (2015) 0.75
Differential Expression of Complement Markers in Normal and AMD Transmitochondrial Cybrids. PLoS One (2016) 0.75
A Novel Complotype Combination Associates with Age-Related Macular Degeneration and High Complement Activation Levels in vivo. Sci Rep (2016) 0.75
THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina (2016) 0.75
Systemic complement activation in central serous chorioretinopathy. PLoS One (2017) 0.75
Complement-Mediated Regulation of Apolipoprotein E in Cultured Human RPE Cells. Invest Ophthalmol Vis Sci (2017) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics (2003) 17.92
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol (1995) 10.05
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 8.38
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet (2005) 6.36
Age-related macular degeneration. N Engl J Med (2006) 5.06
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet (2006) 4.51
Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet (2007) 4.23
The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol (2004) 4.16
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol (2006) 2.80
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am J Pathol (2005) 1.92
Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol (2005) 1.89
His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem (2006) 1.79
Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet (2007) 1.67
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A (2006) 1.63
Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm (1991) 1.41
Multiple testing in the context of haplotype analysis revisited: application to case-control data. Ann Hum Genet (2005) 1.33
Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol (1988) 1.32
Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol (2007) 1.22
Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum (1986) 1.20
The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease. Clin Exp Immunol (1982) 1.15
Complement analysis in the 21st century. Mol Immunol (2007) 0.98
Mutations in splicing factor PRPF3, causing retinal degeneration, form detrimental aggregates in photoreceptor cells. Hum Mol Genet (2007) 0.96
Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol (2002) 0.93
A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm (1991) 0.88
What is lost by digitizing stereoscopic fundus color slides for macular grading in age-related maculopathy and degeneration? Ophthalmology (2004) 0.88
Predictive value of multiple genetic testing for age-related macular degeneration. Arch Ophthalmol (2007) 0.87
Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int (1991) 0.86
Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods (1990) 0.85
Peripheral drusen in membranoproliferative glomerulonephritis type II. Retina (2003) 0.83
Assessment of complement activation in vivo. Immunopharmacology (1993) 0.83
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet (2005) 6.36
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol (2005) 4.35
Age-related macular degeneration. Lancet (2012) 4.17
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet (2008) 4.16
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Fundus autofluorescence imaging: review and perspectives. Retina (2008) 3.22
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol (2007) 3.00
Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet (2003) 2.86
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol (2008) 2.52
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet (2007) 2.36
Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet (2005) 2.34
A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. Hum Genet (2006) 2.27
SNP-based analysis of genetic substructure in the German population. Hum Hered (2006) 2.21
TMEM16B, a novel protein with calcium-dependent chloride channel activity, associates with a presynaptic protein complex in photoreceptor terminals. J Neurosci (2009) 2.19
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
The "diffuse-trickling" fundus autofluorescence phenotype in geographic atrophy. Invest Ophthalmol Vis Sci (2014) 2.06
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol (2007) 2.04
Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology (2007) 2.03
High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 2.03
Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol (2010) 1.98
Methylation at global LINE-1 repeats in human blood are affected by gender but not by age or natural hormone cycles. PLoS One (2011) 1.96
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
An update on the genetics of age-related macular degeneration. Mol Vis (2007) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol (2009) 1.92
Safety of brain 3-T MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology (2008) 1.91
SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis (2008) 1.84
Tidal recruitment assessed by electrical impedance tomography and computed tomography in a porcine model of lung injury*. Crit Care Med (2012) 1.84
Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther (2005) 1.79
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79
CRX ChIP-seq reveals the cis-regulatory architecture of mouse photoreceptors. Genome Res (2010) 1.77
Classification of fundus autofluorescence patterns in early age-related macular disease. Invest Ophthalmol Vis Sci (2005) 1.76
Heterozygous NTF4 mutations impairing neurotrophin-4 signaling in patients with primary open-angle glaucoma. Am J Hum Genet (2009) 1.71
Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci (2008) 1.71
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol (2004) 1.68
X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res (2012) 1.66
Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation. Proc Natl Acad Sci U S A (2013) 1.58
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Risk- and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency. Hum Mol Genet (2011) 1.53
Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet (2002) 1.51
Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol (2006) 1.50
Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol (2009) 1.46
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Transit time flow measurement in on-pump and off-pump coronary artery surgery. J Thorac Cardiovasc Surg (2003) 1.45
Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol (2010) 1.44
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol (2003) 1.44
Macular telangiectasia type 2. Prog Retin Eye Res (2012) 1.44
Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitol Res (2008) 1.42
Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Matrix Biol (2008) 1.42
Increasing the yield in targeted next-generation sequencing by implicating CNV analysis, non-coding exons and the overall variant load: the example of retinal dystrophies. PLoS One (2013) 1.40
Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet (2013) 1.39
Truncating mutation of the DFNB59 gene causes cochlear hearing impairment and central vestibular dysfunction. Hum Mutat (2007) 1.38
Combined confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography imaging of reticular drusen associated with age-related macular degeneration. Ophthalmology (2010) 1.38
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol (2012) 1.38
Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina (2011) 1.37
Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci (2011) 1.36
Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol (2011) 1.36
Coronary MR angiography at 3.0 T versus that at 1.5 T: initial results in patients suspected of having coronary artery disease. Radiology (2005) 1.35
PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure of tooth eruption. Am J Hum Genet (2008) 1.35
Reticular drusen associated with geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 1.34
The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int (2014) 1.34
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci (2006) 1.34
Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology (2013) 1.33
Insertion and topology of normal and mutant bestrophin-1 in the endoplasmic reticulum membrane. J Biol Chem (2006) 1.32
Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol (2012) 1.32
Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2004) 1.31
A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat (2009) 1.30
Safety, feasibility, and diagnostic value of cardiac magnetic resonance imaging in patients with cardiac pacemakers and implantable cardioverters/defibrillators at 1.5 T. Am Heart J (2011) 1.30
Nonsense mutations in FAM161A cause RP28-associated recessive retinitis pigmentosa. Am J Hum Genet (2010) 1.29
Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol (2004) 1.29
Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol (2008) 1.28
ERG variability in X-linked congenital retinoschisis patients with mutations in the RS1 gene and the diagnostic importance of fundus autofluorescence and OCT. Doc Ophthalmol (2007) 1.27
Blindness and visual impairment in Germany: a slight fall in prevalence. Dtsch Arztebl Int (2012) 1.27
Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci (2007) 1.26